Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

Completed

Conditions studied: Metastatic Breast Cancer

In brief

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

Key facts

Study ID

NCT00876070

Run by

SCRI Development Innovations, LLC

People needed

198

Starts

2008-11-01

Expected to finish

2011-02-01

Last updated by the study team

2011-11-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients that have received Abraxane chemotherapy greater than three months from the time of chart review.
• Patients that have received taxane chemotherapy greater than three months from the time of chart review.

Where it is running

• Georgia Cancer Specialists — Atlanta, Georgia, United States
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.